Correlation Between Regen BioPharma and Inhibikase Therapeutics
Can any of the company-specific risk be diversified away by investing in both Regen BioPharma and Inhibikase Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Regen BioPharma and Inhibikase Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Regen BioPharma and Inhibikase Therapeutics, you can compare the effects of market volatilities on Regen BioPharma and Inhibikase Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Regen BioPharma with a short position of Inhibikase Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Regen BioPharma and Inhibikase Therapeutics.
Diversification Opportunities for Regen BioPharma and Inhibikase Therapeutics
0.06 | Correlation Coefficient |
Significant diversification
The 3 months correlation between Regen and Inhibikase is 0.06. Overlapping area represents the amount of risk that can be diversified away by holding Regen BioPharma and Inhibikase Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inhibikase Therapeutics and Regen BioPharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Regen BioPharma are associated (or correlated) with Inhibikase Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inhibikase Therapeutics has no effect on the direction of Regen BioPharma i.e., Regen BioPharma and Inhibikase Therapeutics go up and down completely randomly.
Pair Corralation between Regen BioPharma and Inhibikase Therapeutics
Given the investment horizon of 90 days Regen BioPharma is expected to under-perform the Inhibikase Therapeutics. In addition to that, Regen BioPharma is 2.24 times more volatile than Inhibikase Therapeutics. It trades about -0.22 of its total potential returns per unit of risk. Inhibikase Therapeutics is currently generating about 0.05 per unit of volatility. If you would invest 264.00 in Inhibikase Therapeutics on August 30, 2024 and sell it today you would earn a total of 9.00 from holding Inhibikase Therapeutics or generate 3.41% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Insignificant |
| Accuracy | 95.65% |
| Values | Daily Returns |
Regen BioPharma vs. Inhibikase Therapeutics
Performance |
| Timeline |
| Regen BioPharma |
| Inhibikase Therapeutics |
Regen BioPharma and Inhibikase Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Regen BioPharma and Inhibikase Therapeutics
The main advantage of trading using opposite Regen BioPharma and Inhibikase Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Regen BioPharma position performs unexpectedly, Inhibikase Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inhibikase Therapeutics will offset losses from the drop in Inhibikase Therapeutics' long position.| Regen BioPharma vs. Advanced Proteome Therapeutics | Regen BioPharma vs. ChitogenX | Regen BioPharma vs. Northwest Biotherapeutics | Regen BioPharma vs. Geron |
| Inhibikase Therapeutics vs. DiaMedica Therapeutics | Inhibikase Therapeutics vs. Milestone Pharmaceuticals | Inhibikase Therapeutics vs. Seres Therapeutics | Inhibikase Therapeutics vs. Oncolytics Biotech |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Other Complementary Tools
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |